Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.

Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gómez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martínez MS, Miller G, Rodríguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. doi: 10.1073/pnas.1414221111. Epub 2014 Dec 1. Erratum in: Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764.

2.

Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranes.

Rosling JEO, Ridgway MC, Summers RL, Kirk K, Lehane AM.

J Biol Chem. 2018 Aug 24;293(34):13327-13337. doi: 10.1074/jbc.RA118.003640. Epub 2018 Jul 9.

3.

The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs.

Spillman NJ, Kirk K.

Int J Parasitol Drugs Drug Resist. 2015 Aug 27;5(3):149-62. doi: 10.1016/j.ijpddr.2015.07.001. eCollection 2015 Dec. Review.

4.

Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials.

Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K.

Cell Host Microbe. 2013 Feb 13;13(2):227-37. doi: 10.1016/j.chom.2012.12.006.

5.

Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733.

Crawford ED, Quan J, Horst JA, Ebert D, Wu W, DeRisi JL.

PLoS One. 2017 May 22;12(5):e0178163. doi: 10.1371/journal.pone.0178163. eCollection 2017.

6.

Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.

Vaidya AB, Morrisey JM, Zhang Z, Das S, Daly TM, Otto TD, Spillman NJ, Wyvratt M, Siegl P, Marfurt J, Wirjanata G, Sebayang BF, Price RN, Chatterjee A, Nagle A, Stasiak M, Charman SA, Angulo-Barturen I, Ferrer S, Belén Jiménez-Díaz M, Martínez MS, Gamo FJ, Avery VM, Ruecker A, Delves M, Kirk K, Berriman M, Kortagere S, Burrows J, Fan E, Bergman LW.

Nat Commun. 2014 Nov 25;5:5521. doi: 10.1038/ncomms6521.

7.

Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4.

Turner H.

Future Med Chem. 2016;8(2):227-38. doi: 10.4155/fmc.15.177. Epub 2016 Jan 29. Review.

PMID:
26824174
8.

Reduced deformability of parasitized red blood cells as a biomarker for anti-malarial drug efficacy.

Deng X, Duffy SP, Myrand-Lapierre ME, Matthews K, Santoso AT, Du YL, Ryan KS, Ma H.

Malar J. 2015 Oct 31;14:428. doi: 10.1186/s12936-015-0957-z.

9.

Diverse chemotypes disrupt ion homeostasis in the Malaria parasite.

Lehane AM, Ridgway MC, Baker E, Kirk K.

Mol Microbiol. 2014 Oct;94(2):327-39. doi: 10.1111/mmi.12765. Epub 2014 Sep 15. Erratum in: Mol Microbiol. 2015 Jul;97(1):179.

10.

Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.

Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA.

Science. 2011 Dec 9;334(6061):1372-7. doi: 10.1126/science.1211936. Epub 2011 Nov 17.

11.

Plasmodium falciparum malaria: Convergent evolutionary trajectories towards delayed clearance following artemisinin treatment.

Wilairat P, Kümpornsin K, Chookajorn T.

Med Hypotheses. 2016 May;90:19-22. doi: 10.1016/j.mehy.2016.02.022. Epub 2016 Mar 4.

PMID:
27063079
12.

Correction for Jiménez-Díaz et al., (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.

[No authors listed]

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764. doi: 10.1073/pnas.1518632112. Epub 2015 Oct 1. No abstract available.

13.

Cell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated Antimalarials.

Dennis ASM, Lehane AM, Ridgway MC, Holleran JP, Kirk K.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00087-18. doi: 10.1128/AAC.00087-18. Print 2018 Jun.

14.

A class of potent antimalarials and their specific accumulation in infected erythrocytes.

Wengelnik K, Vidal V, Ancelin ML, Cathiard AM, Morgat JL, Kocken CH, Calas M, Herrera S, Thomas AW, Vial HJ.

Science. 2002 Feb 15;295(5558):1311-4.

15.

Rapid Generation of Marker-Free P. falciparum Fluorescent Reporter Lines Using Modified CRISPR/Cas9 Constructs and Selection Protocol.

Mogollon CM, van Pul FJ, Imai T, Ramesar J, Chevalley-Maurel S, de Roo GM, Veld SA, Kroeze H, Franke-Fayard BM, Janse CJ, Khan SM.

PLoS One. 2016 Dec 20;11(12):e0168362. doi: 10.1371/journal.pone.0168362. eCollection 2016.

16.

Novel molecular targets for antimalarial chemotherapy.

Jana S, Paliwal J.

Int J Antimicrob Agents. 2007 Jul;30(1):4-10. Epub 2007 Mar 6. Review.

PMID:
17339102
17.

Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Phillips MA, Rathod PK.

Infect Disord Drug Targets. 2010 Jun;10(3):226-39. Review.

18.

UK malaria treatment guidelines.

Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, Hill DR, Warrell DA, Bannister BA; HPA Advisory Committee on Malaria Prevention in UK Travellers.

J Infect. 2007 Feb;54(2):111-21. Epub 2007 Jan 9.

PMID:
17215045
19.

Spiroindolones, a potent compound class for the treatment of malaria.

Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT.

Science. 2010 Sep 3;329(5996):1175-80. doi: 10.1126/science.1193225.

20.

Parasite impairment by targeting Plasmodium-infected RBCs using glyceryl-dilaurate nanostructured lipid carriers.

Jain SA, Basu H, Prabhu PS, Soni U, Joshi MD, Mathur D, Patravale VB, Pathak S, Sharma S.

Biomaterials. 2014 Aug;35(24):6636-45. doi: 10.1016/j.biomaterials.2014.04.058. Epub 2014 May 10.

PMID:
24818881

Supplemental Content

Support Center